[1]吴铁雄　刘旭东　朱沪敏　黄 露　李品桦 庞华珍.非酒精性脂肪性肝病对肾功能指标影响的研究进展[J].大众科技,2021,23(6):63-66.
　Research Progress on the Influence of Non-alcoholic Fatty Liver Disease on Renal Function Index[J].Popular Science & Technology,2021,23(6):63-66.
点击复制

非酒精性脂肪性肝病对肾功能指标影响的 研究进展()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
23
期数:
2021年6
页码:
63-66
栏目:
医药与卫生
出版日期:
2021-06-20

文章信息/Info

Title:
Research Progress on the Influence of Non-alcoholic Fatty Liver Disease on Renal Function Index
作者:
吴铁雄1　刘旭东1; 2　朱沪敏1　黄 露1　李品桦1 庞华珍1
（1.广西中医药大学，广西 南宁 530000； 2.广西中医药大学附属瑞康医院，广西 南宁 530000；）
关键词:
非酒精性脂肪性肝病; 慢性肾脏病; 流行病学; 发病机制; 肾脏功能
Keywords:
non-alcoholic fatty liver disease(NAFLD);  chronic kidney disease(CKD);  epidemiology;  pathogenesis mechanism;  renal function
文献标志码:
A
摘要:
酒精性脂肪性肝病是目前世界上常见的肝病之一，其发病率正不断升高。迄今为止，已有许多研究均指出非酒精性脂肪性肝病与慢性肾脏病显著相关。文章通过介绍目前为止两者的流行病学概述，以及归纳非酒精性脂肪性肝病与肾功能指标的诸多相关研究，简单总结了非酒精性脂肪性肝病可能引起慢性肾脏病的可能的机制。
Abstract:
Non-alcoholic fatty liver disease(NAFLD) is one of the common liver diseases in the world at present, and its incidence rate is increasing. So far, many studies have pointed out that NAFLD is significantly related to chronic kidney disease(CKD). This article briefly summarized the possible mechanism of NAFLD causing chronic kidney disease by introducing the epidemiological overview of the two so far, as well as many related studies on NAFLD and renal function indexes.

参考文献/References:

[1]　Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta- analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64(1): 73-84. [2] Giovanni T, Amedeo L, D B C. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus[J]. Endocrinology, 2018, 14(2): 99-114. [3] Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer[J]. International Immunopharmacology, 2015, 24(2): 335-345. [4] Aynur U. Noninvasive fatty liver markers predict liver disease mortality in the US population[J]. Hepatology, 2016, 63(4): 1170-1183. [5] Stevens P E, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Annals of Internal Medicine, 2013, 158(11): 825-5. [6] Targher G, Byrne C D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease[J]. Nature Reviews Nephrology, 2017, 13(5): 297-310. [7] Targher G, Chonchol M B, Byrne C D. CKD and nonalcoholic fatty liver disease[J]. American Journal of Kidney Diseases, 2014, 64(4): 638-652. [8] Younossi Z M. Non-alcoholic fatty liver disease-A global public health perspective[J]. Crossref, 2019, 70(3): 531-544. [9] Sherif Z A, Saeed A, Ghavimi S, et al. Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations[J]. Digestive Diseases and Sciences, 2016, 61(5): 1214-1225. [10] Vernon G, Baranova A, Younossi Z M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J]. Alimentary Pharmacology and Therapeutics, 2011, 34(3): 274-285. [11] Marie N, Tom F, Margaret R, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2014, 384(9945): 766-781. [12] Xin G, Jian F. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the study group of liver and metabolism, Chinese society of endocrinology[J]. Journal of Diabetes, 2013, 5(4): 406-415. [13] Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015[J]. Lancet, 2016, 388(10053): 1545-1602. [14] C W A, V N E, L M R, et al. Chronic kidney disease [J]. Lancet, 2017, 389(10075): 165-180. [15] Mallett A, Patel C, Salisbury A, et al. The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia[J]. Orphanet Journal of Rare Diseases, 2014, 9(1): 98. [16] Katharina B, Giovanni G. Prevalence varies across the european general population[J]. Journal of the American Society of Nephrology, 2016, 27(7): 2135-2147. [17] In P J, Hyunjeong B, Hyuk J H. Prevalence of chronic kidney disease in Korea: the Korean national health and nutritional examination survey 2011-2013[J]. Journal of Korean Medical Science, 2016, 31(6): 915-923. [18] Mehedi H, Ipsita S, Das G R, et al. Prevalence of chronic kidney disease in south Asia: a systematic review[J]. BMC Nephrology, 2018, 19(1): 291. [19] 王善志，朱永俊，唐文庄，等. 中国成人及老年人群慢性肾脏病患病率Meta分析[J]. 中国老年学杂志，2017，37(21): 5384-5388. [20] Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/ laser-treated retinopathy in type 2 diabetic patients[J]. Diabetologia, 2007, 51(3): 444-450. [21] Lucia P, Enea B, Marco A G, et al. The impact of nonalcoholic fatty liver disease on renal function in children with overweight/obesity[J]. International Journal of Molecular Sciences, 2016, 17(8): 1218-1218. [22] Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/ laser-treated retinopathy in type 2 diabetic patients[J]. Diabetologia, 2008, 51(3): 301-309. [23] Musso G, Gambino R, Tabibian J H, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis[J]. PLoS Medicine, 2014, 11(7): 1001680. [24] Cocchetto D M, Tschanz C, Bjornsson T D. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance[J]. Therapeutic Drug Monitoring, 1983, 5(2): 161-168. [25] Lau E, Carvalho D, Freitas P. Gut microbiota: association with NAFLD and metabolic disturbances[J]. BioMed Research International, 2015, 2015(2015): 979515. [26] 杜婉星. 非酒精性脂肪性肝病与肾功能相关指标的相关性研究[D]. 乌鲁木齐: 新疆医科大学，2019. [27] 赵锦涵，常江，钏莉雪，等. 非酒精性脂肪肝纤维化程度与慢性肾病的关系[J]. 解放军医学院学报，2019，40(10): 937-942. [28] 李明，赵彤，徐晓华. 高血压合并NAFLD的Scr、BMI、HDL-C检测及其临床意义[J]. 中国实验诊断学，2018，22(3): 393-396. [29] 郭宏，周晓燕，王雪，等. 高尿酸血症对非酒精性脂肪肝肝损害程度的影响[J]. 中华临床医师杂志(电子版)，2012，6(11): 2974-2978. [30] Fernández R C M, Rocío A, Luisa G G M, et al. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)[J]. Revista Espanola De Enfermedades Digestivas: Organo Oficial De La Sociedad Espanola De Patologia Digestiva, 2019, 111(4): 264-269. [31] 寿岚，施军平，张秋玲，等. 非酒精性脂肪肝患者尿酸、25-羟基维生素D和肿瘤坏死因子的检测及临床意义[J]. 中国卫生检验杂志，2019，29(20): 2491-2493，2497. [32] 任习芳，张祎. 成人非酒精性脂肪肝患者早期肾损伤状况及影响因素分析[J]. 检验医学与临床，2018，15(18): 2733-2735，2739. [33] 孙长贵，曾静，孙婉璐，等. 非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析[J]. 实用肝脏病杂志，2017，20(2): 165-170. [34] Sun D, Ye F, Kani H T, et al. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD[J]. Diabetes and Metabolism, 2020, 46(4): 288-295. [35] 张海玉，刘自华. LDH浓度及估计肾小球滤过率与NAFLD关联性的性别差异[J]. 中南医学科学杂志，2018，46(5): 538-539，554. [36] 王梅林，段永强. 血清透明质酸与血肌酐和血尿素氮测定对诊断肾功能的应用评价[J]. 时珍国医国药，2006，17(9): 1851. [37] Liu X, Zhang H, Liang J. Blood urea nitrogen is elevated in patients with non-alcoholic fatty liver disease[J]. Hepato-Gastroenterology, 2013, 60(122): 343-345. [38] 梁灿灿，丁永年，纪文静，等. 乌鲁木齐市维吾尔族非酒精性脂肪性肝病危险因素的评估[J]. 世界华人消化杂志，2015，23(25): 4094-4100. [39] 胡旭，陶然，俞力. 尿微量白蛋白及促甲状腺激素与2型糖尿病合并非乙醇性脂肪性肝病的相关性[J]. 江苏大学学报(医学版)，2017，27(3): 261-264，267. [40] 施娟，范忠祥. 合并非酒精性脂肪肝的肥胖儿童肾功能改变的研究[J]. 实用医院临床杂志，2018，15(5): 136-139. [41] 李永刚，赵娜. 血清中胱抑素C和β2微球蛋白在早期诊断慢性肾衰竭的临床应用[J]. 中国实验诊断学，2017，21(6): 954-957. [42] Anstee Q M, Seth D, Day C P. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease[J]. Gastroenterology, 2016, 150(8): 1728-1744. [43] Musso G, Cassader M, Gambino R. PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease[J]. Hepatology, 2015, 62(2): 658-659. [44] Mantovani A, Zusi C, Sani E, et al. Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease[J]. Diabetes Metab., 2019, 45(5): 480-487. [45] 林胡，傅君芬，陈雪峰，等. 肥胖儿童青少年非酒精性脂肪肝病早期肾功能状况研究[J]. 浙江大学学报(医学版)，2013，42(4): 381-387. [46] Carrero J J, Park S H, Axelsson Jonas, et al. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad[J]. Seminars in Dialysis, 2009, 22(4): 381-386. [47] 胡玲，李宇. 中老年体检人群非酒精性脂肪肝患病率调查及与代谢相关因素的相关性[J]. 实用医学杂志，2017，33(4): 632-635. [48] 周小莉，何兰杰，毕鹏翔. 非酒精性脂肪肝与冠心病严重性的相关性研究[J]. 中华内分泌代谢杂志，2011，27(9): 729-732. [49] 何微，喻陆，高德禄，等. 辛伐他汀和非诺贝特对非酒精性脂肪肝大鼠血清ATGL酶活性和TNF-α水平的影响[J]. 解放军医学院学报，2012，34(3): 279-282. [50] 赵晓芳，唐友明，徐新杰，等. JNK1基因沉默对非酒精性脂肪性肝病小鼠模型高分子量脂联素表达的影响[J]. 临床肝胆病杂志，2019，35(10): 2257-2260.

相似文献/References:

[1]唐 张.尿毒清颗粒对慢性肾脏病 3～4 期患者微炎症状态的影响[J].大众科技,2019,21(09):44.
　Effect of Niaoduqing Granule on Microinflammation in Patients with Stage 3-4Chronic Kidney Disease[J].Popular Science & Technology,2019,21(6):44.
[2]徐霜霜,曹 响,赵 洁,等.益肾泄浊活血法改善非透析慢性肾脏病患者微炎症状态的 meta 分析[J].大众科技,2019,21(09):78.
　Meta-Analysis of Tonify Kidney, Drain Turbidity and Blood-Activating Therapy forMicroinflammation in Non-dialysis Patients with Chronic Kidney Disease[J].Popular Science & Technology,2019,21(6):78.
[3]陈少颖 易新宇 周小博 张荣臻.中医药治疗非酒精性脂肪肝的研究进展[J].大众科技,2018,20(06):68.
[4]陈少颖 易新宇 周小博 张荣臻.黄连温胆汤配合西医治疗非酒精性脂肪性肝病痰瘀互结证[J].大众科技,2018,20(06):77.
[5]胡 雯.中医药治疗慢性肾脏病睡眠障碍的研究进展[J].大众科技,2019,21(05):97.
　Research Progress on Sleep Disorder of Chronic Kidney Disease Treated byTraditional Chinese Medicine[J].Popular Science & Technology,2019,21(6):97.
[6]古训东 黎丽娜.miRNA 在非酒精性脂肪性肝病中的作用研究进展[J].大众科技,2020,22(09):80.
　Advances in the Role of miRNA in Non-alcoholic Fatty Liver Disease[J].Popular Science & Technology,2020,22(6):80.
[7]刘威利　向少伟 韦海敏　钟文露　任倩倩.慢性肾脏病血管钙化中西医治疗研究进展[J].大众科技,2020,22(11):100.
　Research Progress of Traditional Chinese and Western Medicine in the Treatment of Vascular Calcification in Chronic Kidney Disease[J].Popular Science & Technology,2020,22(6):100.
[8]李铁强　蒋　琴.非酒精性脂肪性肝病中医研究进展[J].大众科技,2021,23(1):52.
　Research Progress of Non-alcoholic Fatty Liver Disease in Traditional Chinese Medicine[J].Popular Science & Technology,2021,23(6):52.
[9]韦璐莹 卢清华 张扬武 张荣臻.基于“肠-肝轴”理论对非酒精性脂肪性肝病影响的研究进展[J].大众科技,2022,24(05):88.
　Research Progress on the Influence of "Entero-Hepatic Axis" Theory on Non-Alcoholic Fatty Liver Disease[J].Popular Science & Technology,2022,24(6):88.
[10]黄源铭 杨 浩 陈金娜 谢丽萍.积雪草的作用机制及临床应用现状[J].大众科技,2022,24(11):92.
　Action Mechanism and Clinical Application Status of Centella Asiatica[J].Popular Science & Technology,2022,24(6):92.

备注/Memo

备注/Memo:
【收稿日期】2021-04-12 【基金项目】广西一流学科建设课题“游离脂肪酸诱导NAFLD中肝细胞的焦亡及祛湿活血方的干预作用”（2019XK139）广西科技厅重点研发计划“非酒精性脂肪性肝病肝纤维化进展对全身多系统功能损伤的预警研究”（桂科AB18221009）。 【作者简介】吴铁雄（1993－），男，福建莆田人，广西中医药大学在读硕士研究生，研究方向为肝脏疾病临床与基础。
更新日期/Last Update: 2021-09-14